Scientific Resources for Ultrasensitive Blood-Based Biomarker Detection

Explore scientific resources advancing ultrasensitive protein biomarker detection in blood. Taudia’s library of research posters, application notes, white papers, webinars, and technical articles highlights how the SPLASH™ single-wash proximity ligation assay enables sensitive, specific, and scalable quantitation of low-abundance neurological biomarkers, including pTau-217, BD pTau-217, eMTBR-Tau243, Aβ42, Aβ40, NfL, GFAP, using accessible qPCR workflows. Discover data and practical insights supporting multiplex biomarker analysis, Alzheimer’s disease research, neurodegenerative disease staging, clinical trial screening, and longitudinal brain health monitoring.

Development of an ultrasensitive, scalable Solid Phase Ligation Assay with Single wasH (SPLASH) based immunoassay for the quantitation of LRRK2

Presented at AD/PD 2026

Multi-platform Quantitation Of Alzheimer’s Disease Biomarkers Using A Multiplex Assay Compatible With qPCR and dPCR

Presented at AD/PD 2026

Simultaneous Quantitation of pTau-217, Aβ42, NfL, and GFAP in Plasma Using a Novel Multiplex Assay for Alzheimer’s Disease Staging and Monitoring

Presented at AD/PD 2026

Absolute quantitation of protein enabled by digital proximity ligation assay to enhance quality control of protein reference material

Presented at AAIC 2025

Flexible assay platform for the quantitation of blood-based biomarkers for early detection of Alzheimer’s Disease

Presented at AAIC 2025

Scalable ultrasenstive quantification of blood-based biomarkers for Alzheimer’s Disease

Presented at ADPD 2025

Redefining Alzheimer's Biomarker Detection with Taudia's NeuXplore™

September 30, 2025

Dried Plasma Spot Testing for Alzheimer's Detection Webinar

March 10, 2026

Multiplexed Biomarker Profiling of Alzheimer's Disease Samples

Multiplexed Biomarker Profiling of Alzheimer's Disease Samples

Discover how Taudia’s five-plex SPLASH™ assay enables simultaneous quantitation of pTau-217, Aβ42, Aβ40, NfL, and GFAP from a single plasma sample—delivering high sensitivity, reduced variability, and scalable workflows for Alzheimer’s disease staging and monitoring.

Single-well multiplexing: Quantify multiple proteins from the same sample without sacrificing performance.

Single-well multiplexing: Quantify multiple proteins from the same sample without sacrificing performance.

Learn how SPLASH™ single-well multiplexing provides accurate duplex quantitation of neurodegenerative biomarkers using the same simple workflow as singleplex assays—allowing researchers to measure multiple proteins from one sample without sacrificing performance.

A Novel Dried Plasma Spot (DPS)-Based Workflow for Quantification of Alzheimer's Disease Diagnostic Biomarkers

Explore a novel DPS-based workflow combining ambient-stable sample collection with SPLASH™ ultrasensitive detection to quantify pTau-217 and Aβ42—offering a practical, scalable path to decentralized Alzheimer’s disease screening and longitudinal monitoring.

Blood-Based Biomarker’s for Alzheimer’s: Impact on Clinical Trial Screening

Learn how Taudia’s single-wash SPLASH platform enables fast, accessible, and ultrasensitive blood-based biomarker testing to transform Alzheimer’s diagnosis and accelerate therapeutic development

Multiplex Quantitation of pTau-217, Aβ40, Aβ42, NfL, and GFAP in Bio-Hermes-001 Cohort

See how Taudia’s SPLASH™ AD 5-plex precisely measures pTau-217, Aβ40, Aβ42, NfL, and GFAP from just 12.5 µL of plasma—and improves prediction of amyloid PET positivity.

AD is a growing public health challenge, with the number of affected Americans projected to reach 8.5 million by 2030...